QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

35,144 signal articles · 107 in last 24h · 178,660 total before filter · latest 1h ago

107last 24h

3127last 7d

512● bullish (7d)

311● bearish (7d)

227publishers

All Macro103 Earnings1821 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: ABBVSentiment:bullish neutral bearish show all (incl. clickbait)

MT Newswires2d agoneutral

Argus Adjusts Price Target on AbbVie to $320 From $270

MT Newswires5d agoneutral

BNP Paribas Adjusts Price Target on AbbVie to $269 From $247

MT Newswires6d agoneutral

Canaccord Genuity Adjusts Price Target on AbbVie to $338 From $290

MT Newswires6d agoneutral

Leerink Partners Adjusts Price Target on AbbVie to $325 From $279

MT Newswires6d agoneutral

Goldman Sachs Adjusts Price Target on AbbVie to $313 From $294

MT Newswires6d agobullish

RBC Raises Price Target on AbbVie to $330 From $280, Keeps Outperform Rating

MT Newswires6d agoneutral

Cantor Fitzgerald Adjusts Price Target on AbbVie to $325 From $290

MT Newswires6d agoneutral

Guggenheim Adjusts Price Target on AbbVie to $322 From $288

24/7 Wall St.39d agoneutral

BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength

24/7 Wall St.80d agoneutral

Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead

ABBV CVX MSFT PFE

Investing.com87d agobullish

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Motley Fool102d agobullish

AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?